Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients failing or intolerant to first-line second-generation tyrosine kinase inhibitor treatment: results of the prospective PONS trial - Le Coutre, Philipp; Burchert, Andreas; Saußele, Susanne; Schwarzer, Thekla; Stintzing, Sebastian; Pelzer, Uwe; Bullinger, Lars; Elmaaḡaçlı, Ahmet Hayri; Jehn, Christian-Friedrich; Stegelmann, Frank; Hochhaus, Andreas; Ernst, Thomas; et al. (Acta haematologica, 2025)
Gesehen am 20.10.2025